Publications by authors named "V de Valk"
Background: The hypothesis that a deep learning (DL) model can produce long-term prognostic information from chest X-ray (CXR) has already been confirmed within cancer screening programs. We summarize our experience with DL prediction of long-term mortality, from plain CXR, in patients referred for angina and coronary angiography.
Methods: Data of patients referred to an Italian academic hospital were analyzed retrospectively.
Background: Acute coronary syndrome (ACS), specifically ST-segment elevation myocardial infarction is a major cause of morbidity and mortality throughout Europe. Diagnosis in the acute setting is mainly based on clinical symptoms and physician's interpretation of an electrocardiogram (ECG), which may be subject to errors. ST-segment elevation is the leading criteria to activate urgent reperfusion therapy, but a clear ST-elevation pattern might not be present in patients with coronary occlusion and ST-segment elevation might be seen in patients with normal coronary arteries.
View Article and Find Full Text PDFArticle Synopsis
- European health authorities are increasingly worried about rising prices for new cancer medications that aren't necessarily improving health outcomes, impacting healthcare system sustainability.
- There's a discussion among payers and advisers about various pricing strategies for these new treatments, including effectiveness levels and different pricing models.
- As new cancer drugs and therapies emerge, coupled with high prices and complex discounting, there will likely be more scrutiny and demand for transparency in pricing, especially as patents on existing medicines expire.
Background: For a patient, drug switches are not desirable (either between a brand-name drug and a generic drug, or between two generic drugs of the same active substance). Research into the causes of drug switches, and related adverse drug reactions, is hampered by the absence of quantitative data on drug switches.
Methods: We describe the frequency of drug switches in the Netherlands for a selection of active substances.
We performed a retrospective cohort study in the Dutch patient population to identify active substances with a relatively high number of adverse drug reactions (ADRs) potentially related to drug switching. For this, we analyzed drug switches and reported ADRs related to switching between June 1, 2009, and December 31, 2016, for a selection of 20 active substances. We also compared pharmacovigilance analyses based on the absolute, switch-corrected, and user-corrected numbers of ADRs.
View Article and Find Full Text PDF